Resilience
Resilience is engaged in the manufacturing of cell and gene therapies, vaccines, biologics, and nucleic acids. Resilience partners with other firms in order to help them develop and scale their products.
NewsHeat chart
- Week
- Month
- Year
- Media news
- Corp news
- Combo news
The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice
Company Valuation
- Valuation
- Share Price
- Cumulative Funding
The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.
Funding Round
Funding Amount
Post-Money Valuation
$ Share Price
Series D11 Aug 2023
***
***
$...
Private Equity10 Jan 2023
***
***
$...
Series D6 Jun 2022
***
***
$...
Series C1 Aug 2021
***
***
$...
Series B23 Nov 2020
***
***
$...
Series A1 Jan 2020
***
***
$...
*** - To view the data, please log into your account or create a new one.
Investors
Lux Capital
GV
8VC
New Enterprise Associates
ARCH Venture Partners
Mubadala Investment CompanyNews related to Resilience
Resilience • 28 Mar 2023As US plots biomanufacturing boost, National Resilience nets $410M loan from Defense Department
Resilience will channel the cash toward its goal of building biomanufacturing capacity and capabilities on U.S. soil ...
https://www.fiercepharma.com/manufacturing/white-house-eyes-biomanufacturing-boost-local-producer-national-resilience-adds-410m